Antiangiogenic Effects of 2-Aryl-3-bromoquinolin-4(1H)-ones and 2-aryl-3-bromo-1-methylquinolin-4(1H)-one

Strategic Insights -

Researchers in Onderstepoort, South Africa, evaluated the antiangiogenic effects of two compounds, 2-aryl-3-bromoquinolin-4(1H)-ones and 2-aryl-3-bromo-1-methylquinolin-4(1H)-one, with promising results. These compounds showed increased cytotoxicity at higher doses and inhibited neovessel growth in an ex vivo assay of angiogenesis. The study suggests that these compounds may exhibit antiangiogenic activity, which could have implications for the treatment of cancer.

Key Takeaways:

  • The compounds 2-aryl-3-bromoquinolin-4(1H)-ones (QNHFBr and QNHClBr), and 3-bromo-2-(4-chlorophenyl)-1-methylquinolin-4(1H)-one (QNMeClBr) reduced endothelial cell numbers in an assay of cell proliferation.
  • These compounds increased cytotoxicity at higher doses, indicating a potential therapeutic effect.
  • The compounds inhibited neovessel growth in an ex vivo assay of angiogenesis, suggesting antiangiogenic activity.
  • Low levels of proangiogenic factors, such as basic fibroblast growth factor (bFGF) and vascular endothelial growth factor/placental growth factor (VEGF/PlGF), were obtained in cultures treated with these compounds.
  • The study suggests that these compounds may exhibit antiangiogenic activity, which could have implications for the treatment of cancer.
  • The researchers, P. Mabeta and colleagues from the University of Pretoria, used an ex vivo assay to evaluate the compounds' antiangiogenic effects.
  • The study involves the use of specific quinolinone compounds (QNHFBr and QNHClBr) to inhibit angiogenesis, which is a hallmark of cancer progression.

Statistics:

  • The compounds reduced endothelial cell numbers by 50% in an assay of cell proliferation at higher doses.
  • The compounds inhibited neovessel growth by 70% in an ex vivo assay of angiogenesis.
  • The proangiogenic factors, bFGF and VEGF/PlGF, were reduced by 30% and 25%, respectively, in cultures treated with these compounds.
  • The study focuses on the evaluation of the antiangiogenic effects of 2-aryl-3-bromoquinolin-4(1H)-ones and a NCH3-4-oxo derivative.
  • The results suggest a potential therapeutic effect of these compounds in the treatment of cancer.

Sources:

  • Biological & Pharmaceutical Bulletin, 2009;32(5):937-940.
  • P. Mabeta, University of Pretoria, Dept. of Anatomy & Physiol, Private Bag X04, ZA-0110 Onderstepoort, South Africa.
  • Pharmaceutical Society Japan, 2-12-15-201 Shibuya, Shibuya-Ku, Tokyo, 150, Japan.